Assessment of study quality
The strength of the evidence was graded according to study design. The grades ranged from 1 (the highest grade) corresponding to evidence from at least one proper RCT, to grade 4 (the lowest grade) corresponding to inadequate evidence owing to methodology problems) (see Other Publications of Related Interest no. 3 ). Other aspects of study design (sample size, duration of follow-up and treatment plan) were also evaluated (see Other Publications of Related Interest no.4). The authors do not state how the papers were assessed for validity, or how many of the reviewers performed the validity assessment.
Data extraction
The authors do not state how the data were extracted for the review, or how many of the reviewers performed the data extraction. Information such as the outcomes assessed, median follow-up and sample size were tabulated. Additional information was provided in the text of the review.
Methods of synthesis
How were the studies combined?
The studies were grouped according to the characteristics of the participants and a narrative synthesis was undertaken. The strength of the evidence was graded from 1, the highest grade where the experimental treatment was significantly better (p<0.05), to grade 5 in which the control group was significantly better (see Other Publications of Related Interest no.4). The strength of the treatment recommendations was graded from grade 1, the highest grade where there was evidence of effective treatment, to grade 5 where the treatment had not been adequately evaluated (see Other Publications of Related Interest no.5).
How were differences between studies investigated?
Differences between the studies were mentioned in the text.
Results of the review
The number of studies and participants included in the review was unclear.
1. Treatment recommendation by disease response and International Prognostic Index (IPI) risk (where available). First chemotherapy-sensitive relapse: the treatment recommendation was graded 1 (effective treatment) and the level of evidence was 1 (at least one properly designed RCT). There was one RCT (215 patients) that compared autologous BMT with salvage chemotherapy. Treatment with autologous BMT improved the overall response rate (84% versus 44%), 5-year EFS (46% versus 12%; p=0.001) and 5-year OS (53% versus 32%; p=0.038).
Chemotherapy-resistant relapse and primary refractory disease: the treatment recommendation was graded 4 (inadequately evaluated treatment) and the level of evidence was 2 (well-designed non-randomised controlled trials, cohort, case-control, multiple time series, dramatic results in uncontrolled trials).
First complete remission in patients with low or intermediate-to-low IPI risk: the treatment recommendation was graded 3 (not an effective treatment) and the level of evidence was 1 (at least one properly designed RCT). There was one RCT with 916 patients, of which 520 patients achieved complete remission. There was no significant difference in the 3-year OS or DFS in this subgroup of 520 patients with complete remission who were randomised to chemotherapy or BMT: OS was 71% with chemotherapy versus 69% with BMT (p=0.60),while DFS was 52 and 59%, respectively (p=0.46).
First complete remission in patients with high or intermediate-to-high IPI risk
: the treatment recommendation was graded 1, but there were problems with the study methodology; the level of evidence was 2 (well-designed nonrandomised controlled trials, cohort, case-control, multiple time series, dramatic results in uncontrolled trials).
First partial remission after full-course induction therapy: there was no evidence available. Abbreviated induction therapy (less than 6 cycles of CHOP or less than 12 cycles of MACOP-B or VACOP-B): the treatment recommendation was graded 3, but there were problems with study methodology; the level of evidence was 1. High-dose sequential therapy in untreated patients with intermediate-to-high or high IPI risk: the treatment recommendation was graded 1 and the level of evidence was 1. In the one crossover RCT (98 patients), patients receiving high-dose sequential therapy had significantly increased rates of 7-year EFS compared with patients receiving MACOP-B (76% versus 49%; p<0.004).
High-dose sequential therapy in untreated patients with low or low-to-intermediate IPI risk: the treatment recommendation was graded 4 (inadequate evidence) and there were problems with the study methodology; the level of evidence was 1.
2. Treatment recommendation for transplantation techniques.
The treatment recommendation was graded 4 (inadequate evidence) for double/tandem SCT and the level of evidence was 2. For myeloablative allogeneic SCT, the treatment recommendation and level of evidence were 4 (inadequate evidence) and 2, respectively; there was no evidence available for nonmyeloablative allogeneic SCT. The treatment recommendation was 1 for both autologous BMT and autologous PBSCT, while the levels of evidence were 1 and 3, respectively. For purging, the treatment recommendation was graded 4 (inadequate) and the level of evidence was 2.
For the stem cell mobilization method, the treatment recommendation and level of evidence were 4 (inadequate) and 2, respectively. There was no evidence available for conditioning regimens. The treatment recommendation and level of evidence were both 1 for high-dose sequential therapy in patients with intermediate-to-high or high IPI risk, and 4 (inadequate) and 1, respectively, for high-dose sequential therapy in patients with low or low-to-intermediate IPI risk.
